{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Mosaic&page=2", "query": { "intervention": "Mosaic", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Mosaic&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-26T01:07:01.335Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02296541", "title": "Evaluating the Safety and Immune Response to Three Different DNA HIV Vaccines Administered With a MVA-CMDR Boost Vaccine in Healthy, HIV-Uninfected Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "DNA Nat-B env", "type": "BIOLOGICAL" }, { "name": "DNA CON-S env", "type": "BIOLOGICAL" }, { "name": "DNA Mosaic env", "type": "BIOLOGICAL" }, { "name": "MVA-CMDR", "type": "BIOLOGICAL" }, { "name": "Placebo for DNA Nat-B env", "type": "BIOLOGICAL" }, { "name": "Placebo for DNA CON-S env", "type": "BIOLOGICAL" }, { "name": "Placebo for DNA Mosaic env", "type": "BIOLOGICAL" }, { "name": "Placebo for MVA-CMDR", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 105, "start_date": "2014-12", "completion_date": "2020-07-06", "has_results": false, "last_update_posted_date": "2023-04-24", "last_synced_at": "2026-09-26T01:07:01.335Z", "location_count": 6, "location_summary": "Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 2 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Decatur", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02296541" }, { "nct_id": "NCT06071767", "title": "Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HIV-1-infection" ], "interventions": [ { "name": "ChAdOx1.tHIVconsv1", "type": "BIOLOGICAL" }, { "name": "ChAdOx1.HIVconsv62", "type": "BIOLOGICAL" }, { "name": "MVA.tHIVconsv3", "type": "BIOLOGICAL" }, { "name": "MVA.tHIVconsv4", "type": "BIOLOGICAL" }, { "name": "Vesatolimod (VES)", "type": "DRUG" }, { "name": "GS-5423", "type": "DRUG" }, { "name": "GS-2872", "type": "DRUG" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2024-04-01", "completion_date": "2029-08-01", "has_results": false, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-09-26T01:07:01.335Z", "location_count": 9, "location_summary": "San Diego, California • Atlanta, Georgia • Chicago, Illinois + 6 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT06071767" }, { "nct_id": "NCT05968989", "title": "Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a Mosaic Hexavalent Influenza Vaccine VRC-FLUMOS0116-00-VP (FluMos-v2) in Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Influenza" ], "interventions": [ { "name": "VRC-FLUMOS0116-00-VP( FLUMos-v2)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 30, "start_date": "2023-08-09", "completion_date": "2025-11-01", "has_results": false, "last_update_posted_date": "2026-07-13", "last_synced_at": "2026-09-26T01:07:01.335Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05968989" }, { "nct_id": "NCT07710443", "title": "Safety and Effectiveness of Mosaic for the Treatment of Midface Volume Deficit", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Midface Volume Deficit" ], "interventions": [ { "name": "Injectable dermal implant", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Helios Aesthetics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "22 Years", "maximum_age": null, "sex": "ALL", "summary": "22 Years and older" }, "enrollment_count": 50, "start_date": "2026-09-08", "completion_date": "2028-01-31", "has_results": false, "last_update_posted_date": "2026-08-24", "last_synced_at": "2026-09-26T01:07:01.335Z", "location_count": 5, "location_summary": "Bradenton, Florida • Coral Gables, Florida • Chestnut Hill, Massachusetts + 2 more", "locations": [ { "city": "Bradenton", "state": "Florida" }, { "city": "Coral Gables", "state": "Florida" }, { "city": "Chestnut Hill", "state": "Massachusetts" }, { "city": "Huntington Station", "state": "New York" }, { "city": "Bryn Mawr", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07710443" }, { "nct_id": "NCT03094832", "title": "Study of Miransertib (MK-7075) in Participants With PIK3CA-related Overgrowth Spectrum and Proteus Syndrome (MOSAIC) (MK-7075-002)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome" ], "interventions": [ { "name": "Miransertib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 50, "start_date": "2017-05-16", "completion_date": "2022-04-11", "has_results": true, "last_update_posted_date": "2023-04-13", "last_synced_at": "2026-09-26T01:07:01.335Z", "location_count": 6, "location_summary": "Atlanta, Georgia • Chicago, Illinois • Boston, Massachusetts + 3 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03094832" }, { "nct_id": "NCT04109846", "title": "Pregnancy and Developmental Outcomes After Transfer of Reportedly Aneuploid or Mosaic Embryos", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Aneuploidy", "Mosaicism", "Pregnancy Outcome" ], "interventions": [ { "name": "Non-euploid embryo transfer", "type": "OTHER" }, { "name": "Euploid Transfer", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "FEMALE", "summary": "18 Years to 55 Years · Female only" }, "enrollment_count": 300, "start_date": "2019-04-11", "completion_date": "2039-04-01", "has_results": false, "last_update_posted_date": "2026-04-24", "last_synced_at": "2026-09-26T01:07:01.335Z", "location_count": 1, "location_summary": "Sunnyvale, California", "locations": [ { "city": "Sunnyvale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04109846" }, { "nct_id": "NCT02788045", "title": "Safety, Tolerability and Immunogenicity Study of Different Vaccine Regimens of Trivalent Ad26.Mos.HIV or Tetravalent Ad26.Mos4.HIV Along With Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Ad26.Mos.HIV", "type": "BIOLOGICAL" }, { "name": "Ad26.Mos4.HIV", "type": "BIOLOGICAL" }, { "name": "Clade C gp140", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Janssen Vaccines & Prevention B.V.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 201, "start_date": "2016-07-08", "completion_date": "2022-04-25", "has_results": true, "last_update_posted_date": "2025-05-25", "last_synced_at": "2026-09-26T01:07:01.335Z", "location_count": 9, "location_summary": "Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Decatur", "state": "Georgia" }, { "city": "Silver Spring", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02788045" }, { "nct_id": "NCT01201967", "title": "A Collaborative Care Program to Improve Treatment of Depression and Anxiety Disorders in Cardiac Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Depression", "Generalized Anxiety Disorder", "Panic Disorder" ], "interventions": [ { "name": "Collaborative care", "type": "OTHER" }, { "name": "Usual care", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 183, "start_date": "2010-09", "completion_date": "2013-06", "has_results": true, "last_update_posted_date": "2014-09-25", "last_synced_at": "2026-09-26T01:07:01.335Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01201967" }, { "nct_id": "NCT05968534", "title": "MOSAIC (MOthers' AdvocateS In the Community) for Pregnant Women and Mothers of Children Under 5 With Experience of Intimate Partner Violence (MOSAIC Plus) Open Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Intimate Partner Violence", "Depression", "Posttraumatic Stress Symptom" ], "interventions": [ { "name": "MOSAIC Plus", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Michigan State University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 15, "start_date": "2024-01-12", "completion_date": "2025-04-30", "has_results": false, "last_update_posted_date": "2026-01-29", "last_synced_at": "2026-09-26T01:07:01.335Z", "location_count": 1, "location_summary": "Flint, Michigan", "locations": [ { "city": "Flint", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT05968534" }, { "nct_id": "NCT02771730", "title": "Study to Evaluate the Safety and Immunogenicity of an Oral HIV Vaccine in Healthy, HIV-uninfected Adults", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteer", "HIV Vaccine" ], "interventions": [ { "name": "Ad4-mgag", "type": "BIOLOGICAL" }, { "name": "Ad4-EnvC150", "type": "BIOLOGICAL" }, { "name": "Placebo Comparator", "type": "OTHER" }, { "name": "AIDSVAX B/E", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Emergent BioSolutions", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "ALL", "summary": "18 Years to 49 Years" }, "enrollment_count": 20, "start_date": "2015-03", "completion_date": "2017-02", "has_results": false, "last_update_posted_date": "2024-03-18", "last_synced_at": "2026-09-26T01:07:01.335Z", "location_count": 1, "location_summary": "Redwood City, California", "locations": [ { "city": "Redwood City", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02771730" } ] }